Hepatoma-derived growth factor mRNA (HDGF mRNA)

Hepatoma-derived growth factor (HDGF) mRNA is the transcript encoding the HDGF protein, a potent mitogen and angiogenic factor that is frequently overexpressed in various solid tumors, including liver, lung, and gastric cancers. The mRNA serves as a critical regulatory node for HDGF expression, which drives oncogenic processes such as cell survival, epithelial-mesenchymal transition (EMT), and metastasis through both nuclear and secreted signaling pathways. In many malignancies, the stability of HDGF mRNA is enhanced by N6-methyladenosine (m6A) methylation, a modification catalyzed by METTL3 and recognized by reader proteins like IGF2BP3, which prevents its degradation and promotes tumor progression. Therapeutic strategies targeting HDGF mRNA primarily utilize RNA interference (RNAi) technologies, such as small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs), to specifically silence the gene and deplete the HDGF protein. Preclinical studies have demonstrated that knocking down HDGF mRNA can effectively inhibit tumor growth, induce apoptosis, and increase the sensitivity of cancer cells to other treatments, such as tyrosine kinase inhibitors. As a therapeutic target, HDGF mRNA offers a promising approach to disrupt multiple oncogenic signaling axes by reducing the production of the multifunctional HDGF protein.

Other names

Hepatoma-derived growth factor transcriptHDGF transcriptHRP-1 mRNAHepatoma-derived growth factor messenger RNA

RNA interference (RNAi) mediated degradation of the target mRNA, leading to the knockdown of hepatoma-derived growth factor protein expression.